If you're a customer of the contraceptive skin patch Ortho Evra, listen up: the FDA issued a statement Friday that it will be requiring the product's label to contain a new warning about blot clot risks based on the findings of a new study.

Although this is not the first time blood clots have been associated with Ortha Evra, the findings from a new study will now be added to the existing label warnings. The study concluded that women aged 15-44 could have a higher probability of developing blood clots when using Ortho Evra when compared to other forms of birth control.

What kind of birth control method do you use? The loyalty many women have to birth control methods sometimes needs to be re-evaluated when new information is put forth from the medical community -- and this new warning inclusion qualifies.

In Ortho Evra's case, the estrogen levels sent through the skin by the transdermal patches can be 60 percent higher than those hormone levels given off from actual birth control pills.